Navigation Links
LLS's Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
Date:9/20/2012

160;has committed substantial, multi-year funding to support this collaboration with Onconova as part of TAP.  LLS continues to partner directly with other biotechnology companies through TAP to accelerate the advancement of potential breakthrough therapies towards FDA approval.

LLS proudly recognizes the significant support provided by Edward P. Evans Foundation and Harry T. Mangurian, Jr. Foundation for this project.

About MDS
Myelodysplastic syndromes (MDS) are a group of diseases of the blood and marrow, with varying degrees of severity and life expectancy. In the general population, MDS occurs in 5 per 100,000 people. However, among individuals older than age 70, the incidence increases to between 22 and 45 per 100,000, increasing even further with age.  Most often, people diagnosed with MDS first seek medical attention because they are experiencing fatigue and shortness of breath. MDS may be a primary (de novo) diagnosis or secondary to cancer treatment with chemotherapy and/or radiation therapy. MDS has been known as "smoldering leukemia," or "pre-leukemia," implying that MDS is only serious and problematic if it evolves into AML; this is not the case.

While there has been recent progress toward improving management of MDS, therapeutic options are limited for patients who have drug-resistant or refractory disease. The only potential cure is stem cell transplantation from a donor. However, patients who have MDS may not be candidates for this option due to their advanced age and underlying bone marrow deficit. Novel therapeutic strategies are needed and to date, rigosertib has shown clinical promise in multiple trials.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patien
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. StemGenex to Launch Adult Stem Cell-Based Therapy to Relieve COPD Symptoms
2. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
3. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
5. New gene therapy strategy boosts levels of deficient protein in Friedreichs ataxia
6. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
7. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
8. First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
9. Gold nanoparticles could treat prostate cancer with fewer side effects than chemotherapy
10. Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis
11. Californians Take One Step Closer to Directly Accessing Physical Therapy Services for Immediate Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... WARREN, N.J. , Aug. 26, 2015  Roka ... company focused on providing advanced testing solutions for the ... Thomas, CEO will present at the Sidoti & Company ... The conference will be held at the New York ... the presentation will be available through the investor relations ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
(Date:8/26/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has been informed that Magnum Opus 2 ... Mr. Yuen Kam, chairman of the board of directors ... "Shares") of  Excellent China Healthcare Investment Limited ("KKR SPV") ...
(Date:8/26/2015)... ... ... PRC Clinical, a Clinical Trial Management Expert CRO, will be ... California. The Clinical Trial Management Expert CRO seeks to introduce more California-based sponsors to ... , Stem Cell Meeting on the Mesa on October 7-9 in ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... , Multiporator / Electroporator 2510 , , , , , , ... , Protocol No. 4308 915.512 04/2002 , , ... , , Microorganism , ... Cell type , Bacteria, gram negative, , ...
... , , , , , Multiporator , , , , ... Transfection Protocol , Protocol No. 4308 915.022 11/1999 , ... , , , Cell line ... Transfection with , Plasmid RSV/lacZ (in bidistilled H 2 O), ...
... , , , , , , Multiporator / Electroporator 2510 , , ... , Transformation Protocol , Protocol No. 4308 915.509 ... , , , , , , ... , Cell type , ...
Cached Biology Technology:Escherichia coli DH5 2Escherichia coli DH5 3COS-7 2Clostridium botulinum 2
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Alternating hemiplegia of childhood (AHC) is a very rare ... the body and then the other in devastating bouts ... difficulty walking are common among patients with this diagnosis. ... discovered that mutations in one gene cause the disease ...
... Branch at Galveston researchers have been awarded a two-year, $1.25 ... of custom-growing human lung tissue to make a three-dimensional model ... the size of a dime, will form the core of ... testing new vaccines and drugs and studying disease processes in ...
... This press release is available in German . ... perceive our world in a self-reflective manner is difficult to ... sleep, however, we are not. But there are people, known ... sleep. Studies employing magnetic resonance tomography (MRT) have now been ...
Cached Biology News:Gene discovery set to help with mysterious paralysis of childhood 2Gene discovery set to help with mysterious paralysis of childhood 3UTMB scientists awarded NIH grant for lab-grown lung tissue project 2The seat of meta-consciousness in the brain 2
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
... Protein Staining Solution stains proteins ... electrophoresis (detection limit >= 8 ng ... including washing and destaining processes can ... staining of gel (20 min), proteins ...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Biology Products: